Acadia Pharmaceuticals Files 8-K Report

Ticker: ACAD · Form: 8-K · Filed: 2025-04-16T00:00:00.000Z

Sentiment: neutral

Topics: regulatory-filing, financial-statements, corporate-governance

Related Tickers: ACAD

TL;DR

ACAD filed an 8-K for admin updates and financials. Nothing major disclosed yet.

AI Summary

On April 15, 2025, Acadia Pharmaceuticals Inc. filed an 8-K report. The filing primarily concerns amendments to its Articles of Incorporation or Bylaws and the submission of Financial Statements and Exhibits. No specific financial figures or significant business events were detailed in the provided excerpt.

Why It Matters

This filing indicates administrative updates and the submission of financial documents, which are standard procedures for public companies to maintain regulatory compliance.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for administrative and financial document submission, not indicating any immediate material changes or risks.

Key Players & Entities

FAQ

What specific amendments were made to Acadia Pharmaceuticals Inc.'s Articles of Incorporation or Bylaws?

The provided excerpt of the 8-K filing does not specify the details of the amendments made to the Articles of Incorporation or Bylaws.

What financial statements and exhibits were filed with this 8-K report?

The excerpt states that Financial Statements and Exhibits were filed, but does not list the specific documents included.

What is the primary purpose of this 8-K filing for Acadia Pharmaceuticals Inc. on April 15, 2025?

The primary purpose is to report amendments to its Articles of Incorporation or Bylaws and to file Financial Statements and Exhibits.

Is there any information about recent business developments or material events in this filing?

Based on the provided text, this 8-K filing focuses on administrative and document submission items, and does not detail specific recent business developments or material events.

What is Acadia Pharmaceuticals Inc.'s fiscal year end?

Acadia Pharmaceuticals Inc.'s fiscal year ends on December 31 (1231).

From the Filing

0001193125-25-082809.txt : 20250416 0001193125-25-082809.hdr.sgml : 20250416 20250416161539 ACCESSION NUMBER: 0001193125-25-082809 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250415 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250416 DATE AS OF CHANGE: 20250416 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 061376651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50768 FILM NUMBER: 25843024 BUSINESS ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-558-2871 MAIL ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 8-K 1 d905282d8k.htm 8-K 8-K ACADIA PHARMACEUTICALS INC false 0001070494 --12-31 0001070494 2025-04-15 2025-04-15     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025     Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter)       Delaware   000-50768   06-1376651 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.) 12830 El Camino Real , Suite 400   San Diego , California     92130 (Address of Principal Executive Offices)     (Zip Code) Registrant’s Telephone Number, Including Area Code:  (858)   558-2871 N/A (Former Name or Former Address, if Changed Since Last Report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   ACAD   The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On April 15, 2025, the board of directors (the “Board”) of Acadia Pharmaceuticals Inc. (the “Company”) adopted amended and restated bylaws of the Company (as amended and restated, the “A&R Bylaws”) effective as of such adoption date. The following is a summary of the material changes made to the Company’s amended and restated bylaws in effect prior to the adoption of the A&R Byl

View on Read The Filing